British COVID-19 drug Sotrovimab approved: effective against Omicron
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
British COVID-19 drug Sotrovimab approved: effective against Omicron
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
British COVID-19 drug Sotrovimab approved: effective against Omicron.
Recently, the new coronavirus mutant strain Omicron reported in South Africa has attracted global attention, and the WHO has assessed its overall global risk as “very high”, which means that it may spread widely in the world.
According to foreign media reports, a study published on the preprint server “BioRxiv” showed that a COVID-19 monoclonal antibody drug called “Sotrovimab” is effective against Omicron.
The report pointed out that “Sotrovimab” was developed by the British GlaxoSmithKline (GSK) and the American biotechnology company Vir Biotechnology (VIR).
However, the research has not yet passed peer review.
The research was conducted on a pseudovirus of all variants of the new coronavirus, including key mutations carried by the Omicron strain.
The results showed that the “Sotrovimab” monoclonal antibody was still active against Omicron strain.
Vir CEO Dr. George Scangos (George Scangos) said in a statement that “Sotrovimab” is specially designed.
When the design points out, it takes into account the possible mutation of the virus, and the antibody targets the spike protein. The part where mutations are unlikely to occur.
It is worth mentioning that due to the high infectivity and ability of the Omicron strain to evade vaccine protection, many vaccine companies are developing new vaccines against it.
American vaccine company Moderna CEO Stephane Bancel (Stephane Bancel) has stated that the existing vaccines will be far less effective in dealing with the Omicron strain, and there will be a substantial decline.
At present, the British Medicines and Medical Products Regulatory Agency has approved “Sotrovimab” for the treatment of COVID-19. In addition, the United States, Japan and other countries have also approved “Sotrovimab” for the treatment of COVID-19s.
British COVID-19 drug Sotrovimab approved: effective against Omicron.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
